[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.4046/trd.2010.68.5.273

The Correlation of Brain Natriuretic Peptide (BNP), Pulmonary Arterial Pressure, and St. George Respiratory Questionnaire (SGRQ) and Their Changes with a Trial of an Angiotensin Converting Enzyme Inhibitor

Kim, Myung-A (Department of Internal Medicine, Seoul National University College of Medicine)
Kim, Deog-Kyeom (Department of Internal Medicine, Seoul National University College of Medicine)
Lee, Chang-Hoon (Department of Internal Medicine, Seoul National University College of Medicine)
Chung, Hee-Soon (Department of Internal Medicine, Seoul National University College of Medicine)

Publication Information

Tuberculosis and Respiratory Diseases / v.68, no.5, 2010 , pp. 273-279 More about this Journal

Abstract

Background: Pulmonary hypertension is considered as a poor prognosis factor in patients with chronic obstructive pulmonary disease (COPD). There has been reported brain natriuretic peptide (pro-BNP) is related with increased right ventricular (RV) workloads. However, there are few studies that evaluate the relationship between BNP and pulmonary arterial pressure (PAP), RV function and St. George Respiratory Questionnaire (SGRQ) score in patients with COPD, and the effects of angiotensin converting enzyme inhibitor (ACEI) on these parameters. Methods: Pulmonary function test, echocardiography, blood BNP, and SGRQ score were evaluated in stabilized moderate degree COPD patients ( $FEV_1$ /FVC< 70%, $50%{\leq}FEV_1$ < 80%) aged 45 years and over, without worsening of symptoms within recent 3 months. After treating with ramipril 10 mg for 3 months, the same evaluation was repeated. Results: Twenty-two patients were included in this study. BNP was significantly correlated with PAP (Pearson coefficient ${\rho}=0.51$ , p=0.02), but not with RV ejection fraction (EF) and predicted $FEV_1%$ . The values for predicted $FEV_1%$ showed significant correlation with SGRQ total score and activity score, but not with BNP or PAP. After ramipril treatment, PAP showed significant decrease ( $42.8{\pm}8.1$ vs. $34.5{\pm}4.5mm$ Hg p=0.0003), tricuspid annular plane systolic excursion significant increase ( $21.5{\pm}3.3$ vs. $22.7{\pm}3.1mm$ p=0.009). BNP showed a tendency to decrease without statistical significance ( $40.8{\pm}59.6$ vs. $18.0{\pm}9.1pg/mL$ p=0.55). SGRQ scores showed no significant change. Conclusion: BNP showed significant correlation with resting PAP, which means BNP could be used as markers for pulmonary hypertension. Treatment with ACEI didn't show significant change in the level of BNP, while pulmonary hypertension and RV function were improved.

Keywords

Natriuretic Peptide, Brain; Pulmonary Disease, Chronic Obstructive; Hypertension, Pulmonary; Angiotensin-Converting Enzyme Inhibitors;

Citations & Related Records

Times Cited By SCOPUS : 0

Reference

1	Stolz D, Breidthardt T, Christ-Crain M, Bingisser R, Miedinger D, Leuppi J, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008;133:1088-94. DOI ScienceOn
2	Maeder MT, Brutsche MH, Christ A, Reichlin T, Staub D, Noveanu M, et al. Natriuretic peptides for the prediction of severely impaired peak VO2 in patients with lung disease. Respir Med 2009;103:1337-45. DOI ScienceOn
3	Rubin LJ. Cardiovascular effects of vasodilator therapy for pulmonary arterial hypertension. Clin Chest Med 1983;4:309-19.
4	The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35. DOI ScienceOn
5	The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302. DOI ScienceOn
6	Di Marco F, Guazzi M, Vicenzi M, Santus P, Cazzola M, Pappalettera M, et al. Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: a pilot study. Pulm Pharmacol Ther 2010;23:159-64. DOI ScienceOn
7	Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, Nakashima B, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009;10:45. DOI ScienceOn
8	Kim MA, Kim SH, Zo JH, Hwangbo B, Lee JH, Chung HS. Right heart dysfunction in post-tuberculosis emphysema. Int J Tuberc Lung Dis 2004;8:1120-6.
9	Gemici G, Erdim R, Celiker A, Tokay S, Ones T, Inanir S, et al. B-type natriuretic peptide levels in patients with COPD and normal right ventricular function. Adv Ther 2008;25:674-80. DOI ScienceOn
10	King L, Wilkins MR. Natriuretic peptide receptors and the heart. Heart 2002;87:314-5. DOI
11	Lang CC, Coutie WJ, Struthers AD, Dhillon DP, Winter JH, Lipworth BJ. Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease. Clin Sci (Lond) 1992;83:529-33. DOI
12	Yetkin O, Hacievliyagil SS, Gunen H. Assessment of B-type natriuretic peptide in patients with pneumonia. Int J Clin Pract 2008;62:488-91.
13	He Q, LaPointe MC. Interleukin-1betaregulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. Hypertension 1999;33:283-9. DOI ScienceOn
14	Mueller C, Laule-Kilian K, Scholer A, Perruchoud AP. B-type natriuretic peptide for risk stratification in community- acquired pneumonia. J Intern Med 2005;258: 391-3. DOI ScienceOn
15	Leuchte HH, Baumgartner RA, Nounou ME, Vogeser M, Neurohr C, Trautnitz M, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006;173:744-50. DOI ScienceOn
16	Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptideas a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32. DOI ScienceOn
17	Burke MA, Cotts WG. Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev 2007;12:23-36. DOI ScienceOn
18	Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43:764-70. DOI ScienceOn
19	Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350: 1349-53. DOI ScienceOn
20	Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-88. DOI ScienceOn
21	Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996;76:232-7. DOI ScienceOn
22	Bettencourt P. NT-proBNP and BNP: biomarkers for heart failure management. Eur J Heart Fail 2004;6:359-63. DOI ScienceOn
23	Reesink HJ, Tulevski, II, Marcus JT, Boomsma F, Kloek JJ, Vonk Noordegraaf A, et al. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 2007;84:537-43. DOI ScienceOn
24	Inoue Y, Kawayama T, Iwanaga T, Aizawa H. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med 2009;48:503-12. DOI ScienceOn
25	Mair J, Friedl W, Thomas S, Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest Suppl 1999;230:132-42.
26	Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-91. DOI ScienceOn
27	Hammarstrom E, Wranne B, Pinto FJ, Puryear J, Popp RL. Tricuspid annular motion. J Am Soc Echocardiogr 1991;4:131-9. DOI
28	Logeart D, Lecuyer L, Thabut G, Tabet JY, Tartiere JM, Chavelas C, et al. Biomarker-based strategy for screening right ventricular dysfunction in patients with nonmassive pulmonary embolism. Intensive Care Med 2007;33:286-92. DOI ScienceOn
29	Turini GA, Brunner HR, Gribic M, Waeber B, Gavras H. Improvement of chronic congestive heart-failure by oral captopril. Lancet 1979;1:1213-5.
30	Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducoloné A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189-94. DOI ScienceOn
31	Ghio S, Recusani F, Klersy C, Sebastiani R, Laudisa ML, Campana C, et al. Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol 2000;85:837-42. DOI ScienceOn
32	Passino C, Maria Sironi A, Favilli B, Poletti R, Prontera C, Ripoli A, et al. Right heart overload contributes to cardiac natriuretic hormone elevation in patients with heart failure. Int J Cardiol 2005;104:39-45. DOI ScienceOn
33	Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002;39:131-8. DOI ScienceOn
34	Mariano-Goulart D, Eberle MC, Boudousq V, Hejazi- Moughari A, Piot C, Caderas de Kerleau C, et al. Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure. Eur J Heart Fail 2003;5:481-8. DOI ScienceOn
35	Troisi F, Greco S, Brunetti ND, Di Biase M. Right heart dysfunction assessed with echography, B-type natriuretic peptide and cardiopulmonary test in patients with chronic heart failure. J Cardiovasc Med (Hagerstown) 2008;9:672-6. DOI ScienceOn
36	Stein BC, Levin RI. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998;135:914-23. DOI ScienceOn
37	Pieralli F, Olivotto I, Vanni S, Conti A, Camaiti A, Targioni G, et al. Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol 2006;97:1386-90. DOI ScienceOn
38	Kaul S, Tei C, Hopkins JM, Shah PM. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J 1984;107:526-31. DOI ScienceOn
39	Ishii J, Nomura M, Ito M, Naruse H, Mori Y, Wang JH, et al. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta 2000;301:19-30. DOI ScienceOn